182 related articles for article (PubMed ID: 31141932)
21. Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma.
Arfaoui Toumi A; Blel A; Aloui R; Zaibi H; Ksentinini M; Boudaya MS; Znaidi N; Zidi Y; Aouina H; Rammeh Rommani S
Curr Res Transl Med; 2018 Sep; 66(3):65-70. PubMed ID: 29540329
[TBL] [Abstract][Full Text] [Related]
22. Two different patterns of lung adenocarcinoma with concomitant
Zhao D; Fan J; Peng L; Huang B; Zhu Y; Shi H; Dai X; Nie X
Tumori; 2022 Feb; 108(1):12-18. PubMed ID: 33818198
[TBL] [Abstract][Full Text] [Related]
23. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
25. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
26. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
Serizawa M; Koh Y; Kenmotsu H; Isaka M; Murakami H; Akamatsu H; Mori K; Abe M; Hayashi I; Taira T; Maniwa T; Takahashi T; Endo M; Nakajima T; Ohde Y; Yamamoto N
Cancer; 2014 May; 120(10):1471-81. PubMed ID: 24700479
[TBL] [Abstract][Full Text] [Related]
27. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Gainor JF; Varghese AM; Ou SH; Kabraji S; Awad MM; Katayama R; Pawlak A; Mino-Kenudson M; Yeap BY; Riely GJ; Iafrate AJ; Arcila ME; Ladanyi M; Engelman JA; Dias-Santagata D; Shaw AT
Clin Cancer Res; 2013 Aug; 19(15):4273-81. PubMed ID: 23729361
[TBL] [Abstract][Full Text] [Related]
28. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
29. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
[TBL] [Abstract][Full Text] [Related]
30. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
31. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
32. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.
Kim TJ; Park CK; Yeo CD; Park K; Rhee CK; Kim J; Kim SJ; Lee SH; Lee KY; Yoon HK
J Surg Oncol; 2014 Sep; 110(3):245-51. PubMed ID: 24888607
[TBL] [Abstract][Full Text] [Related]
34. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
35. Real-world applications of the new grading system in lung adenocarcinoma: A study of 907 patients focusing on revealing the relationship between pathologic grade and genetic status.
Liu XL; Li D; Wan WB; Song YL; Li GQ; Lin DL
Ann Diagn Pathol; 2024 Aug; 71():152328. PubMed ID: 38754357
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
[TBL] [Abstract][Full Text] [Related]
37. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
[TBL] [Abstract][Full Text] [Related]
38. Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung.
Mohamad N; Jayalakshmi P; Rhodes A; Liam CK; Tan JL; Yousoof S; Rajadurai P
Br J Biomed Sci; 2017 Oct; 74(4):176-180. PubMed ID: 28705139
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
40. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
